

Att exhibit # 7

Page 1 of 14

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-W

APPLICATION NO.
09/807,512

APPLICANT
Schrier et al.

FILING DATE
April 16, 2001

GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
TS	AL1	WO 95/04542	02/16/1995	WIPO			Yes No
	AM1	WO 96/10413	04/11/1996	WIPO			Yes No
	AN1	WO 97/19169	05/29/1997	WIPO	(only examine the abstract)		Yes X No
	AO1	WO 97/30721	08/28/1997	WIPO	(only examine the abstract)		Yes X No
	AP1	WO 98/32855	07/30/1998	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TS	AR	1	Aarnoudse, C.A., et al., "Interleukin-2-Induced, Melanoma-Specific T Cells Recognize CAMEL, An Unexpected Translation Product of LAGE-1," <i>Int. J. Cancer</i> 82:442-448, Wiley-Liss, Inc. (July 1999).
	AS	1	Bakker, A.B.H., et al., "Analogues of CTL Epitopes With Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope," <i>Int. J. Cancer</i> 70:302-309, Wiley-Liss, Inc. (January 1997).
	AT	1	Blake, J., et al., "Use of Combinatorial Peptide Libraries to Construct Functional Mimics of Tumor Epitopes Recognized by MHC Class I-Restricted Cytolytic T Lymphocytes," <i>J. Exp. Med.</i> 184:121-130, The Rockefeller University Press (1996).

EXAMINER **M.T. Davis**

DATE CONSIDERED
11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
YLS	AL2	WO 99/18206 A2	04/15/1999	WIPO			Yes No
↓	AM2	WO 99/18206 A3	08/05/1999	WIPO			Yes No
30/04	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

YLS	AR	2	Chen, Y.-T., et al., "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:1914-1918, The National Academy of Sciences of the U.S.A. (March 1997).
↓	AS	2	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" <i>Mol. Med. Today</i> 3:261-268, Elsevier Science Ltd. (June 1997).
↓	AT	2	D'Amaro, J., et al., "A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs," <i>Hum. Immunol.</i> 43:13-18, American Society for Histocompatibility and Immunogenetics and Elsevier Science Ltd. (1995).

EXAMINER

M. T. DAVIS

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

✓	AR	3	Dranooff, G., et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:3539-3543, The National Academy of Sciences of the U.S.A. (1993).
↓	AS	3	Drijfhout, J.W., et al., "Detailed Motifs for Peptide Binding to HLA-A*0201 Derived from Large Random Sets of Peptides Using a Cellular Binding Assay," <i>Hum. Immunol.</i> 43:1-12, American Society for Histocompatibility and Immunogenetics and Elsevier Science Ltd. (1995).
↓	AT	3	Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-296, Macmillan Publishers Ltd. (1991).

EXAMINER

M. T. DAVIS

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

W.S.	AR	4	Fearon, E.R., et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response," Cell 60:397-403, Cell Press (1990).
↓	AS	4	Gansbacher, B., et al., "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity," J. Exp. Med. 172:1217-1224, The Rockefeller University Press (1990).
↓	AT	4	Gaugler, B., et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," J. Exp. Med. 179:921-930, The Rockefeller University Press (1994).

EXAMINER

M. T. Davis

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

YLS.	AR	5	Jäger, E., et al., "Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-binding Peptide Epitopes," <i>J. Exp. Med.</i> 187:265-270, The Rockefeller University Press (January 1998).
	AS	5	Kawakami, Y., et al., "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression," <i>J. Immunol.</i> 154:3961-3968, The American Association of Immunologists (1995).
↓	AT	5	Lethé, B., et al., "LAGE-1, A New Gene With Tumor Specificity," <i>Int. J. Cancer</i> 76:903-908, Wiley-Liss, Inc. (June 1998).

EXAMINER

M. T. DAUCS

DATE CONSIDERED 11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Lin, A.Y., et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <i>Science</i> 249:677-679, The American Association for the Advancement of Science (1990).				
	AS	6	Mayordomo, J.I., et al., "Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity," <i>Nat. Med.</i> 1:1297-1302, Nature Publishing Group (1995).				
	AT	6	Nijman, H.W., et al., "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 6:1215-1219, VCH Verlagsgesellschaft mbH (1993).				

EXAMINER

M.T. DAUIC

DATE CONSIDERED

4/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AK	AR	1	Osanto, S., et al., "Clinical Protocol: Immunization with Interleukin-2 Transfected Melanoma Cells. A Phase I-II Study in Patients with Metastatic Melanoma," <i>Hum. Gene. Ther.</i> 4:323-330, Mary Ann Leibert, Inc. (1993).
↓	AS	1	Parker, K.C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-175, The American Association of Immunologists (1994).
↓	AT	1	Parkhurst, M.R., et al., "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues," <i>J. Immunol.</i> 157:2539-2548, The American Association of Immunologists (1996).

EXAMINER

M.T. DAVIS

DATE CONSIDERED 4/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	8	Rammensee, H.-G., et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:179-228, Springer-Verlag (1995).
AS	8	Ruppert, J., et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-937, Cell Press (1993).
AT	8	Schweighoffer, T., "Molecular Cancer Vaccines: Tumor Therapy Using Antigen-Specific Immunizations," <i>Path. Onc. Res.</i> 3:164-176, W.B. Saunders & Company Ltd. on behalf of the Arányi Lajos Foundation (1997).

EXAMINER

M. T. Davis

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Sette, A., et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-5592, The American Association of Immunologists (1994).
	AS	2	Stauss, H.J., et al., "Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:7871-7875, The National Academy of Sciences of the U.S.A. (1992).
	AT	2	Studier, F.W., et al., "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," <i>Methods Enzymol.</i> 185:60-89, Academic Press, Inc. (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	10	Tepper, R.I., et al., "Murine Interleukin-4 Displays Potent Anti-Tumor Activity In Vivo," Cell 57:503-512, Cell Press (1989).
AS	10	Toes, R.E.M., et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," Proc. Natl. Acad. Sci. U.S.A. 94:14660-14665, The National Academy of Sciences of the U.S.A. (December 1997).
AT	10	Tütting, T., et al., "Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo," Eur. J. Immunol. 27:2702-2707, Wiley-VCH Verlag GmbH (October 1997).

EXAMINER

M.T. DAVIS

DATE CONSIDERED 1/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

XAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

YLS	AR	11	van der Burg, S.H., et al., "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-3314, The American Association of Immunologists (1996).
	AS	11	Van den Eynde, B., and Brichard, V.G., "New tumor antigens recognized by T cells," <i>Curr. Opin. Immunol.</i> 7:674-681, Current Biology Ltd. (1995).
✓	AT	11	van Elsas, A., et al., "CTL Recognition of an IL-2 Producing Human Melanoma Vaccine," in <i>Immunology of Human Melanoma, Tumor-Host Interaction and Immunotherapy</i> , Maio, M., ed., IOS Press, p. 165-173 (1996).

XAMINER

M.T. DAVIS

DATE CONSIDERED

11/03/03

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.2200000/EKS/Y-W	APPLICATION NO. 09/807,512
	APPLICANT Schrier et al.	
	FILING DATE April 16, 2001	GROUP To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	van Elsas, A., et al., "Transfection of IL-2 Augments CTL Response to Human Melanoma Cells In Vitro: Immunological Characterization of a Melanoma Vaccine," <i>J. Immunotherapy</i> . 20:343-353, Lippincott-Raven Publishers (September 1997).
	AS	<u>12</u>	Versteeg, R., et al., "c-myc down-regulates class I HLA expression in human melanomas," <i>EMBO J.</i> 7:1023-1029, IRL Press Limited (1988).
	AT	<u>12</u>	Wang, R.-F., et al., "A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames," <i>J. Immunol.</i> 161:3596-3606, The American Association of Immunologists (October 1998).

EXAMINER	M. T. DAVIS	DATE CONSIDERED	11/03/03
----------	-------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Wölfel, T., et al., "Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes," <i>Eur. J. Immunol.</i> 24:759-764, VCH Verlagsgesellschaft mbH (1994).
	AS	<u>13</u>	Wu, T.-C., et al., "Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92:11671-11675, The National Academy of Sciences of the U.S.A. (1995).
	AT	<u>13</u>	Zitvogel, L., et al., "Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-associated Cytokines," <i>J. Exp. Med.</i> 183:87-97, The Rockefeller University Press (1996).

EXAMINER

M.T. DAVIS

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0652.2200000/EKS/Y-WAPPLICATION NO.
09/807,512APPLICANT
Schrier et al.FILING DATE
April 16, 2001GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

als	AR	14	Dialog File 351, Accession No. 11320204, Derwent WPI English language abstract for WO 97/19169 (Document AN1).				
↓	AS	14	Dialog File 351, Accession No. 11456955, Derwent WPI English language abstract for WO 97/30721 (Document A01).				
	AT						

EXAMINER

M. T. DAVIS

DATE CONSIDERED

11/03/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.